AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) — XBiotech Inc. XBIT today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized clinical study to evaluate Natrunix as a new treatment for Arthritis. Natrunix blocks a key cause of inflammation involved in pain and joint destruction in rheumatoid…Read More
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis RA Clinical Trial XBiotech NASDAQXBIT
